What type of study is this?

This is a Phase 3 study (also classified as: Observational).

Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan

View Full Paper

Ask AI

Bookmark

Authors

FRESCO-2 subgroup analysis shows improved overall and progression-free survival with fruquintinib, indicating strong efficacy in refractory mCRC.

Fruquintinib improved overall survival by 1.3 months compared to placebo in patients with refractory metastatic colorectal cancer.
Hazard ratio for overall survival was 0.42, indicating a significant survival benefit for fruquintinib over placebo.
Patients enrolled in the study showed a higher incidence of grade ≥ 3 treatment-emergent adverse events with fruquintinib than with placebo.
The findings from this Japan subgroup support the overall efficacy and manageable safety of fruquintinib in treating refractory mCRC.

Kotani et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

FRESCO-2 subgroup analysis shows improved overall and progression-free survival with fruquintinib, indicating strong efficacy in refractory mCRC.